About
Gur Roshwalb is CEO of 1E Therapeutics and Board Observer at CPTx. He has experience spanning clinical medicine, sell-side research, buy-side investing, and clinical development, with a track record of building and managing private and public life science companies from startup through Phase II development.
Experience
- CPTxBoard Observercurrent2024 — presentGermany
- 1E TherapeuticsChief Executive Officercurrent2024 — presentRehovot, Center District, Israel
- KAHR-medical Ltd.Board Member2021 — 2024
- Biosplice TherapeuticsBoard Member2021 — 2024United States
- AltruBio Inc.Board Member2020 — 2024
- MiNA TherapeuticsBoard Member2020 — 2024United Kingdom
- aMoon FundPartner2019 — 2024Israel
- Viracta Therapeutics, Inc.Board Member2020 — 2022
- Zywie Bio LLCCEO2017 — 2018
- GeNO, LLCConsultant2017
- Akari Therapeutics PlcCEO2015 — 2017New York/London
- Celsus Therapeutics, PlcCEO2013 — 2015Greater New York City Area
- Venrock AssociatesVice President2008 — 2013
- Piper JaffrayBiotech Analyst2004 — 2008
- Manhattan Internal Medicine AssociatesInternist, Partner1998 — 2004
- Mount Sinai Medical CenterChief Resident1997 — 1998
Education
- NYU Stern School of BusinessMBA, Finance2002 — 2008
- Icahn School of Medicine at Mount SinaiResidency, Internal Medicine Residency Program1994 — 1997
- Albert Einstein College of MedicineMD, Medicine1990 — 1994
- Columbia UniversityBA, East Asian Languages and Culture/Mathematics1986 — 1990
Skills & more
Non-Executive Director9Board Level7Early Stage Investment7Start-up VenturesDrug DevelopmentPortfolio strategyFinancial Modeling32Informatics3Venture Capital32Private Equity10Due Diligence10Investments7
+12 more
Corporate DevelopmentValuationEquity ResearchMergers & AcquisitionsBiotechnologyInvestor RelationsIpoIPOAnalysisCMCCapital RaisePre-IPOLanguages Hebrew
From Gur's professional profile.
Same school
Also attended NYU Stern School of Business367
Luna SchmidInvestor at GV (Google Ventures)Kaz TeradaVenture Advisor at Monta Vista CapitalNeil FongManaging Director Asia at Burda Principal InvestmentsAlex TosoliniAdvisor at CincyTechMax WechterSenior Director of AI at Lerer HippeauTom MonahanFormer Chairman & CEO, CEB at MissionOG
+ 361 more
Also attended Icahn School of Medicine at Mount Sinai13
Justin RobenyAssociate at Osage University PartnersOmar Njie, MDPrincipal at AlleyCorpVinod MittaVenture Partner at Floating PointTara BishopInvestor at Black Opal VenturesScott GottliebPartner at New Enterprise Associates (NEA)Sharon HuangAssociate at Tau Ventures
+ 7 more
Also attended Albert Einstein College of Medicine3
Also attended Columbia University498
Ben HorowitzCo-founder & General Partner at Andreessen HorowitzDoug LeonePartner at Sequoia Capital; former Global Managing PartnerChris DixonFounder & Managing Partner of a16z crypto at Andreessen HorowitzGabriella GiglioHR & Executive Talent at General CatalystScott BillerInvestor at GV (Google Ventures)Erica VanInvestment Director at Intel Capital
+ 492 more
Shared employers
Also worked at KAHR-medical Ltd.2
Also worked at AltruBio Inc.2
Also worked at aMoon Fund21
Yair SchindelCo-Founder & Managing Partner at aMoonOsnat TiroshChief People Officer & Chief of Staff at aMoonTomer BerkovitzManaging Partner at aMoonTodd SoneGeneral Partner at aMoonMoshic MorGeneral Partner at aMoonYaron DanielyGeneral Partner & Head of aMoon Alpha at aMoon
+ 15 more
Also worked at Venrock Associates77
Yonatan SelaPartner at Square Peg CapitalMark BaileyFounder and Partner Emeritus at DFJPriya BanerjeeSenior Principal at B4 CapitalRyan GilbertFounder and Managing Partner at Launchpad CapitalSean O'MalleyPartner at Launchpad CapitalArif FarooquiVice President, Finance at Cota Capital
+ 71 more
Deals · 1
Viracta TherapeuticsBoard seat
via aMoon · filed Dec 2020 · $40M raise
Attribution from SEC filings, press coverage, and firm rosters.
Colleagues at aMoon
Network1
Investors connected to Gur in public investor directories — a warm-intro map.